Retinal Ischemia Clinical Trial
Official title:
Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease
The object of the study is to compare treatment of iris/angle neovascularization with panretinal photocoagulation (laser) to treatment with panretinal photocoagulation and an anti-angiogenic drug: ranibizumab.
A.To obtain preliminary data on the safety and tolerability of ranibizumab (0.5 mg)in
patients with new or progressive neovascularization of the iris or angle due to retinal
ischemic diseases in addition to treatment with PRP using the incidence and severity of
adverse events identified by subjenc reporting vital signs, and ocular examition.
B.To assess the proportion of patients who fail to experience regression of iris and angle
neovascularization documented by the clinical examination, iris florescein angiography and
gonioscopic evaluation.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03730779 -
Oxygen Therapy for Retinal Ischemia
|
Phase 4 | |
| Completed |
NCT03906383 -
Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning in Patients With Type 1 Diabetes
|
N/A | |
| Active, not recruiting |
NCT03422965 -
Perifoveal Vascular Network Assessed by OCT-Angiography in Type I Diabetes Mellitus
|
N/A | |
| Recruiting |
NCT03061526 -
Spectral-domain Optical Coherence Tomography Findings in Retinal Vessel Occlusion
|
||
| Recruiting |
NCT04038125 -
Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME
|
Phase 4 |